NJ A4628

Mandates all health insurers in New Jersey to cover the purchase and use of continuous glucose monitoring systems when prescribed for the treatment of glycogen storage disease

Applies to hospital service corporations, medical service corporations, health service corporations, individual and group health insurance policies, HMOs, and small employer health benefits plans

Requires the State Health Benefits Commission and School Employees' Health Benefits Commission to include this coverage in contracts they purchase

Coverage must be provided at the same level as any other medical condition under the respective policy or contract

Takes effect on the first day of the seventh month following enactment, applying to all health benefits plans delivered, issued, executed, or renewed after that date